JPRN-UMIN000013202招募中1 期
A phaseI/II study of Erlotinib/Carboplatin/Pemetrexed/Bevacizumab in chemotherapy-naive patients with EGFR mutation positive advanced non-squamous non-small-cell lung cancer - A phaseI/II study of Erlotinib/Carboplatin/Pemetrexed/Bevacizumab in chemotherapy-naive patients with EGFR mutation positive advanced non-squamous non-small-cell lung cancer
Kansai Medical University Hirakata Hospital0 个研究点目标入组 35 人开始时间: 2014年2月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Interstitial pneumonia or pulmonary fibrosis detectable on chest Xp 2)History of radiation therapy for chest 3)With hemosputum 4)With active bleeding 5)Symptomatic brain metastasis 6)With active infectious disease 7)History of serious disease condition 8)With massive pleural effusion or ascitis 9)History of active double cancer 10)need to operation 11) History of pregnancy or lactation 12)History of active psychological disease 13) History of drug allergy
研究者
相似试验
已完成
1 期
Phase I study of Erlotinib with Cisplatin, Pemetrexed, and Bevacizumab for chemotherapy naive advanced non-squamous non small cell lung cancer harboring EGFR mutatioadvanced non squamous non small cell lung cancerJPRN-UMIN000012536Osaka Prefectural Medical Center for Respiratory and Allergic diseases12
招募中
2 期
A phase II study of Erlotinib plus Pemetrexed for Non Small Cell Lung Cancer with T790M negative previously treated with EGFR-TKIon-small cell lung cancerJPRN-UMIN000008033Toho University Omori Medical Center15
已完成
2 期
A phase II study of Erlotinib plus Pemetrexed for previously treated Non Small Cell Lung Canceron-Small Cell Lung CancerJPRN-UMIN000007397Kochi University, School of Medicine, Department of Hematology and Resporatory Medicine27
进行中（未招募）
不适用
A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapy - phase II erlotinib-sorafenib in advanced NSCLCAdvanced non small cell lung cancerEUCTR2007-004625-14-NLVU University Medical Centre48
尚未招募
2 期
A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapyNon small cell lung cancer10038666NL-OMON31390Vrije Universiteit Medisch Centrum48